



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

February 18, 2020

Via E-mail  
Paolo Tombesi  
Chief Financial Officer  
Epizyme, Inc.  
400 Technology Square  
Cambridge, Massachusetts 02139

**Re: Epizyme, Inc.**  
**Form 10-Q for the quarterly period ended September 30, 2019**  
**Exhibit No. 10.2 - Fourth Amendment to the Companion Diagnostics Agreement**  
**dated July 26, 2019 between the Registrant and Eisai Co. Ltd. on the one side and**  
**Roche Molecular Systems, Inc. and Roche Sequencing Solutions, Inc. on the other**  
**side.**  
**Filed October 31, 2019**  
**File No. 001-35945**

Dear Mr. Tombesi:

We have concluded our assessment of your redacted exhibit for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance